Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis

G. Barosi, R. P. Gale

Research output: Contribution to journalArticle

2 Citations (Scopus)
Original languageEnglish
Pages (from-to)740
Number of pages1
JournalLeukemia
Volume29
Issue number3
DOIs
Publication statusPublished - Mar 9 2015

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine
  • Medicine(all)

Cite this

Reply to Passamonti et al : Ruxolitinib and survival improvement in patients with myelofibrosis. / Barosi, G.; Gale, R. P.

In: Leukemia, Vol. 29, No. 3, 09.03.2015, p. 740.

Research output: Contribution to journalArticle

@article{061320bbe8af4e0cbd0659aea1c20980,
title = "Reply to Passamonti et al: Ruxolitinib and survival improvement in patients with myelofibrosis",
author = "G. Barosi and Gale, {R. P.}",
year = "2015",
month = "3",
day = "9",
doi = "10.1038/leu.2014.312",
language = "English",
volume = "29",
pages = "740",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Reply to Passamonti et al

T2 - Ruxolitinib and survival improvement in patients with myelofibrosis

AU - Barosi, G.

AU - Gale, R. P.

PY - 2015/3/9

Y1 - 2015/3/9

UR - http://www.scopus.com/inward/record.url?scp=84924598223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924598223&partnerID=8YFLogxK

U2 - 10.1038/leu.2014.312

DO - 10.1038/leu.2014.312

M3 - Article

C2 - 25363668

AN - SCOPUS:84924598223

VL - 29

SP - 740

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 3

ER -